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Summary
Background: Vertebrate oocytes are arrested at sec-
ond meiotic metaphase by cytostatic factor (CSF) while
awaiting fertilization. Accumulating evidence has sug-
gested that inhibition of the anaphase-promoting com-
plex/cyclosome (APC/C) is responsible for this arrest.
Xenopus polo-like kinase 1 (Plx1) is required for activa-
tion of the APC/C at the metaphase-anaphase transi-
tion, and calcium elevation, upon fertilization/activation
of eggs, acting through calmodulin-dependent kinase
II (CaMKII) is sufficient to activate the APC/C and termi-
nate CSF arrest. However, connections between the
Plx1 pathway and the CaMKII pathway have not been
identified.
Results: Overexpression of Plx1 causes CSF release in
the absence of calcium, and depletion of Plx1 from egg
extracts blocks induction of CSF release by calcium
and CaMKII. Prior phosphorylation of the APC/C inhibi-
tor XErp1/Emi2 by CaMK II renders it a good substrate
for Plx1, and phosphorylation by both kinases together
promotes its degradation in egg extracts. The pathway
is enhanced by the ability of Plx1 to cause calcium-
independent activation of CaMKII. The results identify
the targets of CaMKII and Plx1 that promote egg acti-
vation and define the first known pathway of CSF re-
lease in which an APC/C inhibitor is targeted for degra-
dation only when both CaMKII and Plx1 are active after
calcium elevation at fertilization.
Conclusions: Plx1 with an intact polo-box domain is
necessary for release of CSF arrest and sufficient when
overexpressed. It acts at the same level as CaMKII in
the pathway of calcium-induced CSF release by coop-
erating with CaMKII to regulate APC/C regulator(s),
such as XErp1/Emi2, rather than by directly activating
the APC/C itself.
Introduction
During vertebrate oocyte maturation, the immature oo-
cyte develops into a fertilizable gamete arrested at sec-
ond meiotic metaphase while awaiting fertilization. The
mechanism of meiotic metaphase arrest has been
studied for over 30 yr. In early studies, by microinjecting
cytoplasm from a mature oocyte (unfertilized egg) into
embryonic blastomeres, Masui and Markert found that
the injected blastomere underwent cleavage arrest at
the next mitosis [1]. Cytological analysis of the arrested
blastomere revealed that the cell was arrested at meta-
phase, with a single metaphase spindle lacking centro-*Correspondence: jim.maller@uchsc.edusomes and resembling that seen at meiosis II. Masui
and Markert named this cytoplasmic activity “cyto-
static factor” (CSF). They further speculated that CSF
was responsible for the meiotic arrest at metaphase II
of vertebrate unfertilized eggs, and this hypothesis was
supported by the finding that the CSF activity appeared
during meiosis II and disappeared shortly after fertiliza-
tion in response to elevated free Ca2+ [1].
Recently, a substantial amount of evidence has sug-
gested that regulation of anaphase-promoting com-
plex/cyclosome (APC/C) is responsible for CSF arrest.
The APC/C is a ubiquitin-protein isopeptide ligase (E3)
composed of at least nine conserved subunits, and, in
combination with a ubiquitin-activating enzyme (E1)
and a ubiquitin carrier protein (E2 or UBC), it promotes
ubiquitination and degradation of M phase regulators
by the 26S proteasome at the metaphase-anaphase
transition [2–4]. Of the three ubiquitination compo-
nents, the APC/C is the only one whose activity clearly
oscillates during the cell cycle. In vertebrates, the activ-
ity of the APC/C is regulated in several ways. One in-
volves regulation of Fzy/Cdc20, which binds to the
APC/C and activates it [5]. During arrest at metaphase
by the spindle assembly checkpoint, the spindle-
checkpoint protein Mad2 binds Fzy/Cdc20 to inhibit ac-
tivation of the APC/C by Cdc20 [6–8]. In Xenopus egg
extracts, overexpression of Xenopus Mad2 blocks cal-
cium-induced CSF release, presumably by inhibiting
APC/C-Fzy/Cdc20 activity [5], and endogenous Mad2
is required for establishment of CSF arrest by Mos [9].
Another pathway contributing to CSF arrest is the
cyclin E/Cdk2 pathway [10, 11]. This pathway is inde-
pendent of the Mos/MAPK pathway and appears to
also involve negative regulation of Fzy/Cdc20 because
overexpression of Fzy/Cdc20 overcomes APC/C inhibi-
tion by cyclin E/Cdk2 (B. Grimison and J.M., unpub-
lished data). Previously, it was reported that Early mi-
totic inhibitor 1 (Emi1), a vertebrate homolog of the
Drosophila Rca 1 gene, is able to bind Cdc20, inhibit
the activity of the APC/C, and cause a CSF-like arrest
[12–14]. Depletion of Emi1 from CSF-arrested extracts
was reported to cause spontaneous CSF release. How-
ever, this finding was challenged by a later report show-
ing that Emi1 is not present in CSF-arrested cells at a
level significant enough to participate in regulation of
APC/C activity [15], and Emi1-mediated M-phase arrest
is unaffected by Ca2+, making it distinct from CSF ar-
rest. In addition, during arrest with Emi1, both cyclins
A and B are stabilized [13], whereas during CSF arrest
with Mos or cyclin E/Cdk2, only cyclin B is stabilized
[16–19]. A recent report identified a Xenopus Emi1-
related protein, XErp1, that contains a Cdc20 binding
domain closely related to that present in Emi1 [20]. In-
activation of XErp1, also called Emi2 and referred to as
Emi2 hereafter in this paper, led to premature APC/C
activation and CSF release, and addition of excess
Emi2 to CSF extracts prevented release even in the
presence of calcium [20]. Subsequent work showed
that some antibodies to Emi1 also coimmunoprecipi-
tate Emi2 [21]. This suggests that Emi2, not Emi1, is the
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estingly, Xenopus Polo-like kinase 1 (Plx1) phosphory-
lates Emi2 at sites that target it for degradation by the
SCF pathway, hence promoting CSF release [20].
The involvement of Plx1 in regulation of CSF arrest
was initially suggested by the observation that the ad-
dition of kinase-dead Plx1 to CSF extracts blocked cal-
cium-induced CSF release [22–24], indicating a require-
ment for Plx1 activity in APC/C activation. This result
was further supported by the finding that the meta-
phase-anaphase transition was blocked by immunode-
pletion of Plx1, and addition of recombinant Plx1 re-
stored the transition [23]. The effect of Plx1 on CSF
release requires an intact polo-box domain [24, 25]. It
was suggested that rather than activating the APC/C
directly, Plx1 might work by removing an inhibitor of the
APC/C [23]. However, because Plx1 is fully active at
metaphase [26], it is unclear why Plx1-dependent
phosphorylation effects would be restricted to ana-
phase. Under physiological conditions, CSF arrest is re-
leased upon fertilization, which causes a transient rise
in the level of free calcium within the cell. In Xenopus
cell-free extracts, the target of elevated calcium is cal-
modulin-dependent protein kinase II (CaMK II); specific
inhibition of CaMK II prevented calcium-induced CSF
release, and a constitutively active CaMK II mutant
(CamCat) caused CSF release in extracts even in the
absence of calcium [27–29]. Here, we report that Plx1
is a necessary component in the pathway of calcium-
induced CSF release, and recombinant Plx1 protein is
sufficient to trigger CSF release even in the absence of
calcium. We also studied the relationship between Plx1
and CaMK II because each is necessary for CSF re-
lease and sufficient when overexpressed. It was found
that Plx1 and CaMK II require each other in order to
induce CSF release in the absence of calcium, and
overexpression of Plx1 elevates calcium-independent
activity of CaMK II. Further investigation showed that
most likely both Plx1 and CaMK II achieve activation of
the APC/C and CSF release through dual phosphoryla-
tion of Emi2 to promote its degradation.
Results
For this study, we generated two Xenopus Plx1 mutants
in addition to wild-type Plx1 (see Figure S1 in the Sup-
plemental Data available with this article online) [24]:
Plx1NA, a kinase-dead Plx1 whose kinase activity is
abolished by a N172A point mutation in its kinase do-
main [26]; and Plx1WF, a kinase-active Plx1 with a
W408F point mutation in its first polo box, a mutation
equivalent to the W414F mutation in Plk1, which has
been demonstrated to dramatically abolish the localiza-
tion capability of the polo-box domain (PBD) [30]. This
mutation also blocks the effects of Plx1 or Plx1NA on
multiple mitotic steps, including CSF release, in Xeno-
pus [24]. As described in the Experimental Procedures,
the Plx1, Plx1NA, and Plx1WF proteins were expressed
in insect cells and purified to homogeneity by a combi-
nation of affinity (Talon beads) and ion-exchange (Mono
S) chromatography (see Supplemental Data). The re-
combinant proteins were highly concentrated, above 5
mg/ml as measured by the Bradford assay and quantifi-
cation of stained gels.Plx1 Causes CSF Release in the Absence of Calcium
in a Polo-Box-Dependent Manner
So far, all evidence based on loss of Plx1 function indi-
cates that Plx1 is required for activating the proteolytic
machinery for mitotic exit, but it has not been deter-
mined whether enhanced expression of Plx1 is suffi-
cient to cause CSF release. In this study, active, highly
purified Plx1 and the two Plx1 mutants were used in the
Xenopus cell-free system to study the effects of Plx1 on
mitotic exit. To Xenopus egg extracts arrested in meta-
phase by CSF we added recombinant Plx1 to a level
10–15-fold over the endogenous level and found that
without the addition of calcium, Plx1 alone caused mi-
totic exit as judged by the degradation of cyclin B1
(Figure 1A) and histone H1 kinase activity (data not
shown). The addition of the same amount of Plx1NA
did not cause release, indicating Plx1 kinase activity is
required for CSF release. It was noted that the CSF re-
lease caused by Plx1 was somewhat slower than that
induced by calcium (Figure 1A), a result similar to that
seen previously with release induced by CamCat in the
absence of calcium [28]. This is consistent with evi-
dence that several different pathways lead to APC/C
inhibition and CSF arrest during oocyte maturation [31],
and presumably at egg fertilization/activation, multiple
pathways act in concert to activate the APC/C and pro-
mote rapid CSF release.
We have previously shown that an intact PDB is re-
quired for Plx1 to function properly at multiple points
during mitosis [24]. In particular, Plx1NA blocked cal-
cium-induced CSF release, whereas Plx1NA with a
W408F mutation in its first polo box did not block re-
lease. This suggested that Plx1NA was competing with
endogenous Plx1 for PBD binding site(s), and this bind-
ing might be required for Plx1 to phosphorylate its sub-
strate(s) and activate the proteolytic machinery. These
results raise the question of whether Plx1-induced CSF
release is also polo box dependent. To address this is-
sue, we added Plx1WF to CSF-arrested Xenopus egg
extracts; as predicted, the cyclin B1 level remained
high even 80 min after the addition of Plx1WF (Figure
1B), whereas cyclin B1 was undetectable 40 min after
the addition of wild-type Plx1, indicating the release of
CSF activity. New cyclin synthesis restored cyclin B1 to
its original level 80 min after Plx1 addition, indicating
re-establishment of CSF arrest at the next M phase as
expected. This result and previous evidence indicate
that both inhibition and induction of CSF release by
Plx1NA and Plx1, respectively, require a functional
PBD.
The above results showed that Plx1 is sufficient to
induce CSF release in a polo-box-dependent manner.
It is unclear, however, whether Plx1 is part of the path-
way by which calcium and CaMK II induce CSF release.
To determine whether Plx1 is required for calcium-
induced CSF release, we first completely immuno-
depleted endogenous Plx1 from metaphase-arrested
Xenopus egg extracts (Figure 2A). Upon calcium addi-
tion to the Plx1-depeleted extracts, the cyclin B1 level
remained high even 40 min after calcium addition (Fig-
ure 2A), whereas the same amount of calcium caused
CSF release in mock-depleted extracts. It was noted
that in the Plx1-depleted CSF extracts, the cyclin B1
level remained stable when no calcium was added,
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Absence of Calcium in a Polo-Box-Depen-
dent Manner
As a result of the activity of CSF, a Xenopus
egg extract (CSF extract) is arrested at meta-
phase of meiosis II with a high level of cyclin
B protein. Upon the addition of calcium, CSF
arrest is released, anaphase commences,
and B type cyclins are destroyed by the
APC/C.
(A) To CSF-arrested extracts recombinant
Plx1 or Plx1NA was added to a level 15-fold
over endogenous Plx1, and CSF release in
the absence of calcium was monitored by
the degradation of cyclin B1 (upper panel).
Control extracts were incubated with or
without calcium addition, and cyclin B deg-
radation was monitored as indicated. Lower
panel shows immunoblot of His-tagged re-
combinant Plx1 proteins added to the ex-
tracts.
(B) In the upper panel, CSF extracts were
supplemented with or without calcium, and
the level of cyclin B1 was monitored. In the
lower panel, recombinant Plx1 or Plx1WF
was added to the CSF extracts in the ab-
sence of calcium, and the degradation of
cyclin B1 was monitored by immunoblotting
at the indicated times.suggesting that Plx1 is not required for maintenance of
CSF arrest.
To extend the above loss-of-function result and elimi-
nate the potential codepletion of other important com-
ponents, we performed rescue experiments. In sepa-
rate experiments, we determined that the addition of
recombinant Plx1 to CSF extracts to a level 2-fold over
the endogenous level did not cause CSF release in the
absence of calcium (data not shown). Therefore, to
Plx1-depleted CSF extracts we added recombinant
Plx1 to 2-fold over the undepleted endogenous level
and observed restoration of calcium-induced CSF re-
lease (Figure 2B). As controls, the same level of recom-
binant Plx1 did not cause CSF release in the absence
of calcium, and cyclin B remained stable in the Plx1-
depleted extracts even when calcium was added (Fig-
ure 2B). These results support the hypothesis [23] that
Plx1 is a necessary component in the pathway of cal-
cium-induced CSF release.
Plx1 and CamCat Require Each Other to Induce CSF
Release in a Calcium-Independent Manner
Previously, it has been reported that CaMK II is required
for calcium-induced CSF release [28] because inhibi-
tion of CaMK II blocks CSF release when calcium is
added [27, 28]. Moreover, a calcium-independent con-
stitutively active kinase fragment of CaMK II (CamCat)
is sufficient to induce CSF release in a calcium-inde-
pendent manner [28]. Because either Plx1 or CaMK II
expression can induce CSF release, it is important to
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nd, in particular, to determine whether they act in inde-
endent pathways or whether one is upstream of the
ther in the pathway of CSF release. To address this
uestion, we first purified the constitutively active mu-
ant of CaMK II (CamCat) and characterized its action
n CSF extracts. As shown in Figure S2, purified Cam-
at was added to CSF extracts at two final concentra-
ions as indicated. At both final concentrations, Cam-
at was able to induce CSF release in the absence of
alcium, consistent with a previous report [28]. For fu-
ure experiments, a final concentration of 30 ng/l
amCat was used.
Because both Plx1 and CaMK II are necessary for
SF release, it is possible that they act in the same
olecular pathway to control CSF release. In this case,
f one kinase is upstream of another, depletion or inhibi-
ion of that kinase might block the ability of the other
inase to induce CSF release. It is also possible that
oth kinases act at the same level but need the activity
f each other to pass the signal to downstream tar-
et(s), e.g., to phosphorylate their substrate(s). To dis-
inguish between these possibilities, we first com-
letely immunodepleted Plx1 from CSF extracts (Figure
A) and then added CamCat at a concentration that
auses spontaneous CSF release in mock-depleted ex-
racts (Figure 3A). We also added calcium to one ali-
uot of the Plx1-depleted extract; although in this ex-
eriment some cyclin B degradation occurred, nuclear
orphology verified that this was not sufficient to
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Induced CSF Release
(A) Complete depletion of Plx1 from CSF ex-
tracts is shown in the left panel. The right
panel shows the level of cyclin B1 at the indi-
cated times in extracts depleted of wild-type
Plx1 in the presence and absence of
calcium.
(B) The left panel shows depletion of Plx1.
The right panel shows cyclin B1 levels in
Plx1-depleted extracts with or without cal-
cium addition and with or without an add-
back of Plx1 to a final level 2-fold over the
wild-type level. Similar results were obtained
in several independent experiments.cause CSF release and exit from M-phase, demonstrat-
ing functional depletion of Plx1. It was found that Cam-
Cat could not trigger CSF release in Plx1-depleted ex-
tracts, indicating that CaMK II is not a downstream
component of the pathway of Plx1-mediated CSF re-
lease. To extend this observation, we added CamCat to
a CSF extract containing Plx1NA to determine whether
CamCat can overcome inhibition of CSF release by ki-
nase-dead Plx1. In accordance with the Plx1 depletion
result, CamCat was unable to overcome inhibition of
CSF release by Plx1NA (Figure 3B).
Next, we employed the CaMK II-specific inhibitor
peptide, 281–309, to inhibit endogenous CaMK II activ-
ity [27] in order to evaluate whether Plx1 is able to trig-
ger CSF release in the absence of CaMK II activity. As
shown in Figure 3C, the inhibitor peptide 281–309 not
only blocked calcium-induced CSF release as reported
previously [27] but also inhibited the ability of Plx1 to
induce CSF release. This latter event was surprising be-
cause it suggested that basal activity of CaMK II was
necessary for Plx1-induced CSF release. To investigate
this point further, we performed CaMK II assays in ex-
tracts by using a specific peptide substrate that en-
compasses the sequence around Thr286 in the auto-
regulatory region of CaMK II, which is associated with
enzyme activation [32]. As shown in Figure 4, calcium
addition to a CSF extract led to rapid CaMK II activa-
tion, peaking at 1–2 min and returning to a sustained
activity level above basal by 5 min. Studies of CaMK II
in other systems have suggested the sustained activity
of CaMK II long after a calcium stimulus reflects the
activity of CaMK II phosphorylated at Thr286 [32].
These kinetics are similar to those reported previously
for CaMK II during CSF release with a phosphospecific
antibody to Thr286 [27]. Basal activity against the
CaMK II substrate (inhibitable by the 281–309 peptide)
was not detectable in a control extract, but remarkably,
CaMK II activity was significantly generated upon addi-
tion of Plx1 (Figure 4). The increase was completely
blocked by inclusion of the inhibitor peptide 281–309
but was largely insensitive to the inclusion of BAPTA
and EGTA, indicating elevation of the calcium-indepen-
dent activity of CaMK II. Because CaMK II phosphory-lated on Thr286 is known to exhibit activity even in the
absence of calcium [32], this suggests the possibility
that Plx1 promotes phosphorylation of Thr286 to gener-
ate calcium-independent activity of CaMK II. The
mechanism is not yet clear but is likely to be indirect
inasmuch as CaMK II is not a substrate for Plx1 in vitro
(data not shown).
Overexpression of Xenopus Mad2 Blocks CSF
Release Induced by either Plx1 or CamCat
Overexpression of Mad2 blocks calcium-induced CSF
release by binding the APC/C activator Fzy/Cdc20
and inhibiting Fzy/Cdc20-dependent activation of the
APC/C [6]. When overexpressed, both Plx1 and Cam-
Cat are sufficient to induce CSF release in the absence
of calcium, indicating their ability to ultimately activate
the APC/C for degradation of mitotic regulators. There-
fore, it was important to determine whether overexpres-
sion of Mad2 would block CSF release triggered by
Plx1 and/or CamCat because this would help clarify
whether the APC/C itself was a direct target of Plx1
and/or CamCat. When recombinant Xenopus Mad2
was added to CSF extracts, CSF release induced by
calcium was completely blocked (Figure 5Ab). In addi-
tion, the amount of Plx1 and CamCat able to induce
CSF release in the absence of calcium (Figure 5Aa)
failed to trigger CSF release in the presence of Mad2
(Figure 5Ab). This result was also verified by sperm
nuclear morphology (Figure 5A, lower panel). This result
strongly suggests that neither Plx1 nor CaMK II pro-
motes CSF release by directly activating the APC/C;
rather, they most likely regulate the APC/C through acti-
vating regulator(s) such as Cdc20 or removing inhibi-
tors that affect Cdc20-dependent activation. This con-
cept is consistent with evidence that antisense ablation
of Fzy/Cdc20 in maturing oocytes blocks egg activation
(CSF release) by the calcium ionophore A23187 [33]
and that the addition of antibody to Fzy/Cdc20 to CSF
extracts blocks Ca2+-induced CSF release [5]. How-
ever, our study does not exclude the possibility that
either kinase might phosphorylate subunits of the
APC/C at sites that are insufficient for activation.
To further verify action through effects on Fzy/Cdc20,
Current Biology
1462
Plx1 and CaMK II Cooperate to Promote CSF Release
1463Figure 4. CaMK II Activity in Egg Extracts Is Increased by Plx1
As indicated, CSF extracts were supplemented with either buffer,
calcium, Plx1 + (281–309), Plx1 + (BAPTA + EGTA [10 mM each]),
or Plx1 alone, and endogenous CaMK II activity in the absence of
added calcium was measured as described in the Experimental
Procedures. The level of CaMK II activity upon buffer addition was
not reduced by inclusion of the 281–309 inhibitor peptide (data
not shown).we immunodepleted Fzy/Cdc20 from CSF extracts. As
shown in Figure 5B, there was no detectable Fzy/Cdc20
remaining in Fzy/Cdc20-depleted CSF extracts, and
calcium addition to the Fzy/Cdc20-depleted extracts
did not cause CSF release (Figure 5Cb), demonstrating
the efficiency of Fzy/Cdc20 depletion. This result is
consistent with a previous report that depletion of Fzy/
Cdc20 blocks CSF release induced by constitutively
active CaMK II [5]. As expected, addition of either Plx1
or CamCat to the Fzy/Cdc20-depleted extracts also did
not trigger CSF release (Figure 5Cb), whereas the same
amount of Plx1 or CamCat caused CSF release in
mock-depleted extracts (Figure 5Ca). The result was
also confirmed by examining sperm nuclear morphol-
ogy. This result further supports the hypothesis that
both Plx1 and the CaMK II promote CSF release by reg-
ulating APC/C regulator(s) rather than by activating the
APC/C directly.Figure 3. Plx1 and CamCat Require Each Other to Induce CSF Release
(A) Panel a shows depletion of endogenous Plx1. In (b), CamCat-induced release was monitored with or without Plx1 depletion, and the
corresponding nuclear morphology is shown in the lower panel.
(B) CSF release by CamCat was monitored in the presence of Plx1NA, as indicated. The corresponding nuclear morphology is shown in the
lower panel at the indicated times. Note that the partial degradation of cyclin B in this experiment was insufficient to cause exit from M phase.
(C) In the absence or presence of the CaMK II inhibitor 281–309 at a final concentration of 0.4 mM, CSF release induced by both calcium and
Plx1 was analyzed by immunoblotting cyclin B1. The corresponding nuclear morphology is shown in the lower panel at the indicated times.
it binds a phosphomotif [36]. Importantly, in egg ex-Combined Action of Plx1 and CamCat Overcomes
Inhibition of CSF Release by Emi2 but Not by Mad2
If both Plx1 and CaMK II act in the same pathway on
different components or on two independent pathways,
then the combined action of both kinases might be suf-
ficient to overcome arrest by either Mad2 or Emi2. We
have shown that alone neither Plx1 nor CamCat is able
to overcome Mad2 inhibition of the APC/C (Figure 5Ab).
Further work confirmed that Emi2 inhibits Fzy/Cdc20-
APC/C activity in the presence of calcium, consistent
with a previous report [20]. We found that Emi2 also
inhibited CSF release induced by either Plx1 or CamCat
(Figure 6A). However, as shown in Figure 6B, the combi-
nation of both kinases together did overcome the
APC/C inhibition imposed by expression of Emi2 but
not by Mad2, suggesting that no additional kinase
activities are required to overcome inhibition of APC/C
activation by Emi2.
It has been demonstrated that the Plx1 phosphoryla-
tion-dependent degradation of Emi2 requires the PBD
[20]. The PBD is thought to bind a phosphopeptide mo-
tif in target proteins under conditions in which a “prim-
ing kinase” has phosphorylated the substrate first to
promote docking of the PBD, and this docking en-
hances subsequent Plx1-dependent phosphorylation
[34, 35]. The fact that neither Plx1 nor CamCat alone
was able to overcome the inhibition of Emi2 on the
APC/C, whereas the combination of both kinases did
overcome the inhibition, led us to suspect that CamCat
might act as a priming kinase for Plx1 to generate a
binding site for the PBD, leading to Plx1-dependent
phosphorylation of Emi2 and facilitation of its degrada-
tion. To test our hypothesis, we carried out a series of
in vitro phosphorylation reactions. First, GST-Emi2 was
found to be a good substrate for CaMK II, whereas GST
alone was only marginally phosphorylated (Figure 6C).
Next, GST-Emi2 coupled to Dynabeads was initially
phosphorylated by CaMK II in an assay with unlabeled
ATP; after several washes of the complex, the GST-
Emi2 was then incubated with Plx1 in the presence of
[γ-32P]ATP. It was found that phosphorylation of GST-
Emi2 by Plx1 was clearly enhanced after pretreatment
with CaMK II (Figure 6D, lower panel). At this level of
exposure, no phosphorylation of Emi2 by Plx1 is evi-
dent in the absence of prior phosphorylation by CaMK
II. However, other experiments have confirmed that
some Plx1-dependent phosphorylation of Emi2 can oc-
cur without CaMK II treatment under some conditions,
as reported previously [20]. The increased autophos-
phorylation of Plx1 in the presence of Emi2 that had
undergone priming phosphorylation by CaMK II (Figure
6D) may reflect loss of autoinhibition by the PBD when
Current Biology
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(A) In (a), induction of CSF release in the absence of calcium by either CamCat or recombinant Plx1 protein was assessed by the level of
cyclin B1 (upper panel) or changes in sperm nuclear morphology (lower panel). In (b), in the same experiment, recombinant Xenopus Mad2,
which completely blocked calcium-induced CSF release, also blocked CSF release triggered by either the CamCat or recombinant Plx1
(upper panel). The middle panel shows the level of recombinant Mad2 added as blotted by anti-His antibody. Nuclear morphology is shown
in the lower panel.
(B) Fzy/Cdc20 was not detectable in Fzy/Cdc20-depleted CSF extracts. The lower bands demonstrate the specificity of the immunodepletion.
(C) In (a), both CamCat and recombinant Plx1 were able to induce CSF release in the absence of calcium in mock-depleted CSF extracts. In
(b), depletion of Fzy/Cdc20 from the extracts totally blocked CSF release induced by calcium, CamCat, or recombinant Plx1, as indicated by
the stable cyclin B1 level and nuclear morphology.tracts, Emi2 was degraded only when both Plx1 and
CaMK II were active and able to cause CSF release
(Figure 6E). This result strongly supports a model in
which CaMK II acts as a priming kinase for Plx1 phos-
phorylation of Emi2 at sites that target it for degrada-
tion and presumably release of Fzy/Cdc20 for activa-
tion of the APC/C [20].
Discussion
Several lines of evidence indicate that CSF activity is
established by inhibition of the APC/C by multiple inde-
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tendent pathways [31]. It is evident that regulation of
PC/C activity is also a key element in the maintenance
nd release of CSF arrest. Plx1 has previously been
hown to be required for mitotic exit. In this report, we
sed the Xenopus cell-free system to demonstrate that
lx1 is not only necessary but also sufficient when over-
xpressed to trigger the metaphase-to-anaphase transi-
ion and CSF release. Wild-type recombinant Plx1 and a
onstitutively active mutant of Plx1 have been added
o Xenopus CSF extracts previously, but no effect on
aintenance of CSF arrest was evident after the addi-
ion (Y.-W. Qian, J.L., and J.L.M., unpublished data).
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Cat Overcomes Inhibition by Emi2 but Not
Mad2
(A) CSF release was monitored by immu-
noblotting cyclin B1 at the indicated times in
extracts supplemented with Plx1 or CamCat.
(B) The experiment in (A) was repeated ex-
cept that both kinases together were added,
and release was monitored either in the
presence of Emi2 or Mad2.
(C) An equimolar amount of GST-Emi2 or
GST alone was incubated with either buffer
or CaMK II under the phosphorylation condi-
tion described in the Experimental Pro-
cedures. The GST-Emi2 is substantially
phosphorylated by CaMK II, whereas GST is
only marginally phosphorylated. An autora-
diograph is shown. Similar results were ob-
tained when CamCat was used instead of
CaMK II (data not shown).
(D) The upper panel shows loading of Emi2
or Plx1 where applicable. The lower panel
shows Plx1-dependent phosphorylation of
Emi2 or CaMK II-treated Emi2.
(E) The upper panel shows CSF release in-
duced by combined action of both Plx1 and
CamCat as monitored by a cyclin B2 blot.
The middle panel shows the degradation of
overexpressed GST-Emi2 in the presence of
both Plx1 and CamCat, whereas the GST-
Emi2 is stable in extracts to which only cal-
cium is added. Other experiments demon-
strated that the addition of either CamCat or
Plx1 alone did not cause degradation of ov-
erexpressed GST-Emi2 (data not shown).
The lower panel shows the degradation of
endogenous Emi2 upon calcium addition to
the same extract.Now it is clear that this was due to insufficient expres-
sion levels, only about 3-fold over the endogenous
level. In this study, we added highly purified recombi-
nant Plx1 to CSF extracts at a final concentration of 10–
15-fold over the endogenous Plx1 level and achieved CSF
release even in the absence of calcium. This result sug-
gests that a substrate of Plx1 normally not accessible to
Plx1 before fertilization or calcium addition was phos-
phorylated by excess Plx1 because the kinase activity
of Plx1 was required for CSF release. Moreover, an in-
tact polo box of Plx1 was also shown to be required for
Plx1 function, indicating that a PBD-mediated interac-
tion regulates phosphorylation of the substrate. These
results are consistent with the recent finding that Plx1
phosphorylates Emi2 and targets it for degradation,
thereby relieving inhibition of the APC/C and promoting
CSF release [20]. Although the involvement of Emi1 in
CSF is controversial, it was also shown that Plx1 regu-
lates the stability of Emi1 in a similar manner [37, 38].
In the case of Emi2, its interaction with Plx1 was shown
to be polo box dependent, and depletion of Emi2 abol-
ished the ability of Plx1NA to block calcium-induced
CSF release [20].However, this model raises a question. Because Plx1
activity is high during meiotic metaphase II arrest, why
would a Plx1 substrate(s), e.g., Emi2, not be phosphor-
ylated until after the addition of calcium? There are sev-
eral possibilities. One explanation is that Plx1 and the
substrate(s) are localized differentially, such that only
when Plx1 is translocated to the site where the sub-
strate(s) resides will the phosphorylation occur. Sup-
porting evidence for this scenario comes from the
translocation of Plx1 during mitosis, at which time Plx1
moves from centrosomes and spindle poles to the
metaphase plate and finally to the midbody during cy-
tokinesis [39, 40]. However, this cannot explain the
requirement for Plx1 for CSF release (APC/C activation)
in extracts without added DNA, where a mitotic spindle
does not exist. This suggests a second possibility, that
the polo-box-dependent interaction between Plx1 and
its substrate(s) is dependent upon a third element. A
plausible model involves a priming kinase. It has been
reported that the PBD recognizes an optimal sequence
containing Ser and Thr, and binding of the PBD to the
motif may require phosphorylation by a priming kinase
distinct from Plx1 itself [34, 35]. In support of this
Current Biology
1466model, it has been reported that the interactions be-
tween Plx1 and Cdc25C [41] and between Plx1 and the
checkpoint mediator protein Claspin [42] are PBD-
dependent and that binding of the PBD to Cdc25C or
Claspin requires prior phosphorylation by a distinct
priming kinase to generate a docking site for the PBD.
In the case of regulation of CSF activity, it is possible
that the phosphorylation of Plx1 substrate(s) also re-
quires priming by a distinct kinase to generate a PBD
binding site in the substrate itself (Figure 7) that brings
the Plx1 catalytic domain into proximity with its sub-
strate. Because the interaction between Plx1 and Emi2
is PBD-dependent and because CaMK II is required for
Plx1 to induce CSF release, it seems likely that CaMK
II may act as a priming kinase for phosphorylation of
Emi2 to generate a docking site for the PBD, thereby
promoting the Plx1-dependent phosphorylation of
Emi2 at sites that target it for degradation, leading to
activation of the APC/C and CSF release. This model
gains strong support from the finding that CaMK II was
able to phosphorylate Emi2 in vitro (Figure 6C) and that
this phosphorylation in turn enhanced the ability of Plx1
to phosphorylate the APC/C inhibitor. Moreover, only
the combined action of both kinases in extracts was
able to cause degradation of Emi2 and overcome CSF
arrest (Figure 6E). These results explain why Plx1 is
needed for CSF release at anaphase even though the
enzyme is fully active at metaphase during CSF arrest,
and they also identify a key target of CaMK II for cal-
cium-induced CSF release at fertilization.
However, neither Plx1 nor CamCat alone or the com-
bination of both kinases was able to overcome inhibi-
tion of the APC/C by Mad2. Mad2 inhibits APC/C activ-
ity by binding to the positive APC/C regulator Fzy/
Cdc20. It has been reported that the binding of Mad2
to Fzy/Cdc20-APC/C is regulated by phosphorylation
[43], and phosphorylated Mad2 is unable to bind to
Fzy/Cdc20. Although we found that both Plx1 and
CaMK II were able to phosphorylate Mad2 in vitro to a
certain extent (data not shown), phosphorylation by
both kinases in CSF-arrested extracts did not relieve
Mad2 inhibition of APC/C activation by Fzy/Cdc20,
suggesting that another pathway is responsible for
Mad2 phosphorylation/inactivation. It is notable that
depletion of Mad2 does not trigger CSF release [9],
whereas depletion of Emi2 does cause release [20], in-
dicating that Emi2 is sufficient to inhibit Fzy/Cdc20 and
maintain CSF arrest in the absence of calcium. Another
pathway involved in CSF arrest is cyclin E/Cdk2, whose
ability to inhibit the APC/C is removed by Tyr15 phos-
phorylation of Cdk2 after calcium addition [11]. It is
possible the partial cyclin B degradation seen in some
extracts in the absence of Plx1 (Figure 3A), albeit not
sufficient for M phase exit, reflects calcium-dependent
inactivation of the Mad2 or cyclin E/Cdc2 APC/C inhibi-
tory pathway.
It is clear that calcium- and CaMK II-induced CSF
release requires Plx1, demonstrating that Plx1 is proba-
bly a physiological component of the CSF regulation
machinery. In any case, a surprising result was that CSF
release in response to Plx1 overexpression still requires
CaMK II because the CaMK II inhibitory peptide
blocked the effects of Plx1. The ability of Plx1 to ele-
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mi2 inhibits the activation of the APC/C by Fzy/Cdc20. Upon the
ddition of calcium, CaMK II is activated and phosphorylates Emi2
priming), generating a docking site for the PBD of Plx1, which sub-
equently binds to and further phosphorylates Emi2. The phos-
horylation by Plx1 targets Emi2 for degradation by the SCF (Skp1-
ullin F-box) ubiquitin ligase complex, leading to CSF release.ate calcium-independent CaMK II activity explains
hy the inhibitor peptide 281–309 was able to block
lx1-dependent CSF release, and it reinforces the con-
ept in our model (Figure 7) that Plx1 and CaMK II re-
uire each other to cooperate in relief of APC/C inhibi-
ion by Emi2. In addition to activation of CaMK II by
alcium, it is evident that there is an apparent positive
eedback loop between these kinases during CSF re-
ease, a loop in which Plx1 may promote elevated activ-
ty of CaMK II, which then phosphorylates Emi2 to pro-
ote PBD binding to Emi2 and elevation of Plx1 activity
oward Emi2 (Figure 6). This positive feedback loop
ay contribute to the rapidity of APC/C activation at
ertilization because Plx1 is already fully active at meta-
hase [26].
onclusions
lx1 has been previously shown to be required for the
etaphase-to-anaphase transition. Here, we have shown
hat overexpression of Plx1 alone is sufficient to trigger
ctivation of the APC/C and release from CSF arrest.
y studying the relationship between Plx1 and CaMK
I, a kinase previously demonstrated also to be suffi-
ient to trigger CSF release, we found that Plx1 and
aMK II are mutually dependent upon each other to
nduce CSF release. It is therefore evident that both
lx1 and CaMK II cooperate to promote activation of
he APC/C and the release of CSF arrest. It was demon-
trated that, rather than activating the APC/C directly,
oth Plx1 and CaMK II activate the complex by regulat-
ng Fzy/Cdc20. A plausible model involves CaMK II as
priming kinase to generate a docking site for PBD
inding, which enables Plx1 to phosphorylate its sub-
trate(s) and activate the APC/C. One candidate sub-
trate is Emi2, whose interaction with Plx1 is PBD-
ependent and whose phosphorylation by Plx1 targets
t for ubiquitin-mediated degradation. Our data show
hat phosphorylation of Emi2 by Plx1 is substantially
nhanced if the substrate is prephosphorylated by
aMK II, and the combination of Plx1 and CamCat can
vercome inhibition of CSF release by Emi2 by tar-
Plx1 and CaMK II Cooperate to Promote CSF Release
1467geting it for degradation. The dual phosphorylation of
Emi2 by Plx1 and CaMK II is further enhanced by the
ability of Plx1 to activate CaMK II activity in a calcium-
independent manner.
Experimental Procedures
Constructs and Protein Purification
Plx1 and its mutants Plx1NA and Plx1WF were generated as de-
scribed previously [24]. A baculovirus encoding a constitutively
active fragment (amino acids 1-280) of CaMK II (CamCat) was a gift
from M.D. Browning (Department of Pharmacology, UCHSC). The
Plx1, Plx1NA, or Plx1WF proteins were purified with Talon beads,
and this was followed by Mono S chromatography as described
previously [26]. CamCat bearing a T7 tag was purified with a T7
Tag Affinity Purification Kit (Novagen) following the manufacturer’s
protocol. Emi2 was cloned by PCR amplifying the DNA from a Xen-
opus stage VI oocyte cDNA library (Stratagene) with the primers
5#-GACGACGACAAGATGGCAAATCTCTTAGAG-3# and 5#-GAGGA
GAAGCCCGGTCTAGCTTCAAAGTCTC-3#, with subsequent clon-
ing into the pET41 ek/LIC vector (Novagen) following the manufac-
turer’s protocol. This vector produces a recombinant protein having
both GST and 6His tags. GST-Emi2 was purified with Glutathione
Sepharose 4B beads (Amersham Biosciences). The pET41 GST
was prepared by cleaving a portion of GST-Emi2 on the Glutathione
beads with thrombin protease (Amersham Biosciences). After sev-
eral washes with PBS, GST was eluted from the beads with 10 mM
glutathione (Sigma).
In Vitro Phosphorylation
For in vitro phosphorylation of GST-Emi2, equal amounts of GST-
Emi2 (0.3 M) and pET41 GST (0.3 M) were incubated with either
buffer or 50 ng of CaMK II (Upstate) in the presence of 0.5 mM
CaCl2, 5 M calmodulin (Calbiochem), and 100 M [γ−32P]ATP
(1500 cpm/pmole) at 30°C for 10 min. For in vitro phosphorylation
of either buffer-treated or CaMK II-treated GST-6His Emi2 by Plx1,
an equal amount of Emi2 was bound to Dynabeads Protein G (Dy-
nal) precoupled with anti-His monoclonal antibody (Sigma) and in-
cubated as above in the presence of 100 M cold ATP with either
buffer or 50 ng of CaMK II in buffer containing calcium and calmod-
ulin (Calbiochem). After washing the Dynabeads/Emi2 complex 5
times with PBS, the beads were incubated with an equal amount
(100 ng) of Plx1 in the presence of 100 M [γ−32P]ATP at 30°C for
10 min. The reaction was stopped by addition of 4× SDS gel sample
buffer, electrophoresed on a 10% SDS-PAGE gel, and analyzed by
autoradiography or immunoblotting. For CaMK II assay, the CaM
Kinase II Assay Kit (Upstate) was used, and the manufacturer’s pro-
tocol was followed. The autocamtide 2 substrate (KKALRRQETV-
DAL) is based on the sequence around CaMK II’s autoregulatory
phosphorylation site (Thr286), which is associated with activation
of calcium-independent CaMK II activity [32]. Other experiments
demonstrated that Plx1 did not phosphorylate autocamtide 2 spe-
cifically, and Plx1 activity toward casein was not inhibited by the
281–309 peptide (data not shown).
Preparation and Manipulation of CSF Extracts, Sperm
Nuclear Morphology, and Immunoblotting
CSF extracts were prepared as described previously [44]. These
extracts are arrested at metaphase of meiosis II with a high level
of cyclin B/Cdc2 activity as a result of the activity of CSF. Upon
the addition of calcium, the arrest is released, causing exit from
metaphase and proteolysis of mitotic cyclins by the APC/C. Each
individual reaction was made by transferring on ice 40 µl of extract
into a 0.5 ml microcentrifuge tube containing about 8000 Xenopus
sperm nuclei and then adding buffer or recombinant proteins to the
following final concentrations unless otherwise indicated: 150 ng/
µl for Plx1, Plx1NA, or Plx1WF; 30 ng/µl for CamCat; and 120 ng/µl
for Mad2. After a 10 min incubation on ice, CSF arrest was released
by the addition of 0.4 µl of 50 mM CaCl2 when applicable, and
incubation was carried out at 21°C. Samples of 1 µl were taken at
the indicated times, mixed with 4 µl of fixation/stain buffer (48%
glycerol, 11% formaldehyde, 1× MMR [100 mM NaCl, 2 mM KCl,
1 mM MgSO , 2 mM CaCl , and 5 mM HEPES (pH 7.5)], and 1 µg/4 2ml DAPI), and sperm nuclei morphology was monitored by fluores-
cence microscopy. One microliter of sample at each time point was
mixed with 20 µl of Laemmli Sample Buffer (BioRad) and boiled for
5 min. For immunoblotting, 10 µl of each sample, equivalent to 0.5
µl of extract, was used. Cyclins B1 and B2 were detected with
sheep anti-cyclin B antibodies prepared as described previously
[44], and Emi2 was monitored with rabbit anti His-Emi2 (1–374) an-
tibodies that were affinity purified on a column of GST-Emi2.
Supplemental Data
Supplemental Data include two figures and are available with this
article online at: http://www.current-biology.com/cgi/content/full/
15/16/1458/DC1/.
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